Table 4 Clindamycin susceptibility pattern among erythromycin resistant isolates (n = 147)
| Â | MRSA | MSSA | Total |
|---|---|---|---|
iMLSB | 19 (12.9%) | 12 (8.1%) | 31 (21.0%) |
cMLSB | 37 (25.2%) | 42(28.5%) | 79 (53.4%) |
MS Phenotype | 7 (4.76%) | 30 (20.4%) | 37 (25.17%) |
| Â | MRSA | MSSA | Total |
|---|---|---|---|
iMLSB | 19 (12.9%) | 12 (8.1%) | 31 (21.0%) |
cMLSB | 37 (25.2%) | 42(28.5%) | 79 (53.4%) |
MS Phenotype | 7 (4.76%) | 30 (20.4%) | 37 (25.17%) |